Opus Genetics Inc (IRD) Stock Price, Quote & News

Company Profile

Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal do...

Industry: Biotechnology

Sector: Healthcare

Phone: 984 884 6030

Website: opusgtx.com

Address:

8 Davis Drive, Suite 220, Durham, United States

TruthTooPower Feb. 23 at 12:02 PM

$INDP!!! $IRD !!! $ZCMD !!! !!!!!!!!!!!!!!!!🤓!!!!!!!!!!!!!!!!!

0 · Reply

bondia Feb. 19 at 4:23 AM

$IRD SCHEDULE 13G Perceptive Advisors LLC Aggregate Amount Beneficially Owned by Each Reporting Person 7,174,154.00 Percent of class represented by amount in row 9.99 % https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=319786960&type=PDF&symbol=IRD&cdn=63334b521a6eec7b94b43f6405e397b7&companyName=Opus+Genetics+Inc.&formType=SCHEDULE+13G%2FA&formDescription=%5BAmend%5D+Statement+of+acquisition+of+beneficial+ownership+by+individuals&dateFiled=2026-02-17

0 · Reply

Sciguy67 Feb. 18 at 6:27 PM

$IRD time to take some profit

0 · Reply

signaljumper Feb. 18 at 5:01 PM

$IRD Looks Like that Most of the Stocks that bought in the 2's and 3's are Long holding Position for a srock price that will be a lot of Higher than now. All new buyers will Bring the Stock Up. With good Data this Stock could trade in Double Digits area. Only some more buying and WE will Break the 4's

0 · Reply

NocturneTrades Feb. 18 at 7:10 AM

$IRD IRD or unknown micro-cap with minimal public information and likely a shell or dormant issuer.

0 · Reply

TruthTooPower Feb. 18 at 1:22 AM

$AUUD!!! $ENSC !!! $INDP !!! $SCNI !!! $IRD !!!

0 · Reply

TruthTooPower Feb. 18 at 1:03 AM

$AUUD!!! $IRD !!! You Know What I Have 2 of My Largest Holdings and Highest Gainers Born From (A Bag Just Like This) That Were Given As A Share From a Spin Off or Result of Mergers Buyouts!!! That I’ve had for a year… up 300% Example $IRD Right Here!!!

0 · Reply

ifinitis Feb. 17 at 9:02 PM

$IRD Looking for a Bump to $6.00 plus!

0 · Reply

TruthTooPower Feb. 17 at 8:33 PM

$AUUD!!! $ENSC !!! $IRD !!! $INDP !!! !!!!!!!!!!!! ;) !!!!!!!!!!!

0 · Reply

Zeyas Feb. 17 at 7:37 PM

$IRD I missed this one 🫤, congratulations to you guys

1 · Reply

Opus Genetics: Asymmetric Upside With LCA5 And BEST1

Feb 13, 2026, 7:30 AM EST - 10 days ago

Opus Genetics Announces $25 Million Private Placement

Feb 2, 2026, 8:00 AM EST - 21 days ago

Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026

Jan 27, 2026, 7:00 AM EST - 27 days ago

Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa

Jan 15, 2026, 3:26 PM EST - 5 weeks ago

Opus Genetics, Inc. (IRD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 8, 2026, 7:00 AM EST - 6 weeks ago

Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts

Dec 16, 2025, 4:01 PM EST - 2 months ago

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 11, 2025, 7:00 AM EST - 2 months ago

Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference

Dec 9, 2025, 7:00 AM EST - 2 months ago

Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease

Nov 20, 2025, 8:00 AM EST - 3 months ago

Opus Genetics to Participate in Upcoming Investment Conferences

Nov 13, 2025, 7:00 AM EST - 3 months ago

Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease

Nov 12, 2025, 7:00 AM EST - 3 months ago

Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update

Nov 6, 2025, 7:00 AM EST - 3 months ago

Opus Genetics Announces $23 Million Registered Direct Offering

Nov 6, 2025, 7:00 AM EST - 3 months ago

Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease

Oct 14, 2025, 8:00 AM EDT - 4 months ago

Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference

Oct 2, 2025, 8:00 AM EDT - 5 months ago

Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025

Sep 30, 2025, 12:12 PM EDT - 5 months ago

Opus Genetics, Inc. - Special Call

Sep 30, 2025, 7:00 AM EDT - 5 months ago

Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

$Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions$

Sep 4, 2025, 8:00 AM EDT - 6 months ago

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Sep 3, 2025, 8:00 AM EDT - 6 months ago

Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:00 AM EDT - 6 months ago

Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

Aug 27, 2025, 8:00 AM EDT - 6 months ago

Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September

Aug 18, 2025, 8:00 AM EDT - 6 months ago

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

Aug 13, 2025, 4:30 PM EDT - 6 months ago

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

Aug 5, 2025, 8:00 AM EDT - 7 months ago

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Jul 23, 2025, 8:00 AM EDT - 7 months ago

Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness

Jul 3, 2025, 4:30 PM EDT - 8 months ago

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 26, 2025, 6:55 AM EDT - 8 months ago

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Jun 23, 2025, 8:00 AM EDT - 8 months ago

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program

$Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions$

Jun 2, 2025, 8:00 AM EDT - 9 months ago

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

May 15, 2025, 8:00 AM EDT - 10 months ago

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

May 12, 2025, 8:00 AM EDT - 10 months ago

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May

May 6, 2025, 8:00 AM EDT - 10 months ago

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

May 5, 2025, 8:00 AM EDT - 10 months ago

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

Apr 11, 2025, 3:47 PM EDT - 11 months ago

Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns

Apr 8, 2025, 8:00 AM EDT - 11 months ago

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Apr 2, 2025, 8:00 AM EDT - 11 months ago

Opus Genetics to Participate in Upcoming Investor Conference in April

Mar 31, 2025, 8:20 AM EDT - 11 months ago

Opus Genetics Announces Financial Results for Full Year 2024

Mar 21, 2025, 5:03 PM EDT - 1 year ago

Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics

Mar 21, 2025, 9:30 AM EDT - 1 year ago

Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

Mar 21, 2025, 9:11 AM EDT - 1 year ago

Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million

Mar 5, 2025, 8:00 AM EST - 1 year ago

Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Feb 26, 2025, 8:00 AM EST - 1 year ago

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Feb 18, 2025, 7:30 AM EST - 1 year ago

Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program

Feb 7, 2025, 9:15 AM EST - 1 year ago

Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.

XBI

Dec 19, 2024, 8:00 AM EST - 1 year ago

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

TruthTooPower Feb. 23 at 12:02 PM

$INDP!!! $IRD !!! $ZCMD !!! !!!!!!!!!!!!!!!!🤓!!!!!!!!!!!!!!!!!

0 · Reply

bondia Feb. 19 at 4:23 AM

0 · Reply

Sciguy67 Feb. 18 at 6:27 PM

$IRD time to take some profit

0 · Reply

signaljumper Feb. 18 at 5:01 PM

0 · Reply

NocturneTrades Feb. 18 at 7:10 AM

$IRD IRD or unknown micro-cap with minimal public information and likely a shell or dormant issuer.

0 · Reply

TruthTooPower Feb. 18 at 1:22 AM

$AUUD!!! $ENSC !!! $INDP !!! $SCNI !!! $IRD !!!

0 · Reply

TruthTooPower Feb. 18 at 1:03 AM

0 · Reply

ifinitis Feb. 17 at 9:02 PM

$IRD Looking for a Bump to $6.00 plus!

0 · Reply

TruthTooPower Feb. 17 at 8:33 PM

$AUUD!!! $ENSC !!! $IRD !!! $INDP !!! !!!!!!!!!!!! ;) !!!!!!!!!!!

0 · Reply

Zeyas Feb. 17 at 7:37 PM

$IRD I missed this one 🫤, congratulations to you guys

1 · Reply

GladEator Feb. 17 at 5:40 PM

$OCUL Maybe consider $IRD

0 · Reply

bondia Feb. 17 at 5:15 PM

$IRD https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=319783348&type=PDF&symbol=IRD&cdn=7e53eb9754cd6aeccf456cbfb952e500&companyName=Opus+Genetics+Inc.&formType=SCHEDULE+13G&formDescription=Statement+of+acquisition+of+beneficial+ownership+by+individuals&dateFiled=2026-02-17 SCHEDULE 13G Balyasny Asset Management L.P. Aggregate Amount Beneficially Owned by Each Reporting Person 5,110,373.00 Percent of class represented by amount in row 7.41 %

0 · Reply

signaljumper Feb. 17 at 4:20 PM

$IRD looking for a Break of the 4 bucks area this week

0 · Reply

MochiMeerkat Feb. 17 at 4:14 PM

$HOTH $IRD $VNET $COCH _\_\

0 · Reply

DenaliLife Feb. 17 at 4:08 PM

$IRD Started a new position here. Will test the waters.

0 · Reply

bondia Feb. 17 at 7:40 AM

$IRD total instis now : 32.59 % https://www.nasdaq.com/market-activity/stocks/ird/institutional-holdings

0 · Reply

bondia Feb. 17 at 7:38 AM

$IRD 7,123,506.00 shares owned Nantahala Capital Management, LLC + 1,435,407 https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=319781795&type=PDF&symbol=IRD&cdn=88d7d04230d16d3b85527e1233662b3c&companyName=Opus+Genetics+Inc.&formType=SCHEDULE+13G%2FA&formDescription=%5BAmend%5D+Statement+of+acquisition+of+beneficial+ownership+by+individuals&dateFiled=2026-02-13shares total instis mow : 32.59 % new : Adage Capital Partners Gp, L.L.C. with 954,996 shares blackrock up 207% and intel said : Insider Ownership 57.12 % https://fintel.io/sn/us/ocup

0 · Reply

Big_Zack22 Feb. 17 at 1:44 AM

$IRD +5 this week 🔥

0 · Reply

OfficialStocktwitsUser Feb. 16 at 10:38 PM

$IRD RSI: 66.67, MACD: 0.3238 Vol: 0.47, MA20: 2.74, MA50: 2.37 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

signaljumper Feb. 15 at 6:35 PM

Trading Opportunities $NOW $PYPL $EQ.X $AKBA $IRD follow my blog with free sign in and look at the trigger points. https://www.patreon.com/posts/trading-for-week-150851059?utm_medium=social&utm_source=twitter&utm_campaign=postshare_creator&utm_content=join_link

0 · Reply

signaljumper Feb. 14 at 9:25 AM

$IRD what we think about the News from Yesterday. Sign in for free and find more intesting articels https://www.patreon.com/posts/150683489?utm_campaign=postshare_creator&utm_content=android_share&utm_source=twitter

0 · Reply

DGains Feb. 13 at 9:06 PM

$IRD Shhh!! 🤫 !! 💵💹 Been Screaming Buy since < $1 🤑😎 When volume hits.. $RIME Boom!! 💥 $$$ $RYCEY Rolls-Royce 🏎️💎 Tooo Easy @ .87 avg 💎🛫 $BTC.X Let’s GOO!! 🔥

1 · Reply

Market Cap	233.79M
Revenue (ttm)	10.99M
Net Income (ttm)	-57.53M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-523.48%
Debt to Equity Ratio	0.18

Volume	433,500
Avg Vol	823,182
Day's Range	N/A - N/A
Shares Out	68.96M
Stochastic %K	40%
Beta	0.58
Analysts	Strong Sell
Price Target	$7.75